



**AN EXCITING TECHNOLOGY  
FOR THE TREATMENT OF  
YOUR GLAUCOMA.**

**iStent**  
TRABECULAR  
MICRO-BYPASS

**iSTENT:**  
**MANAGE YOUR**  
**GLAUCOMA**

iStent works like the stents used to prevent heart attacks and strokes. When blood vessels get clogged, a stent creates access to the vessel flow.

While it's a highly innovative technology, how iStent works is elegantly simple:

- If you have glaucoma, over time your eye's natural drainage system becomes clogged
- iStent creates a permanent opening through the blockage to improve the eye's natural fluid outflow
- By improving the outflow of fluid in your eye, iStent is designed to lower and control the pressure within your eye

If iStent sounds like something you're interested in, talk to your doctor. He or she will be able to answer other questions you might have.

If he or she agrees that iStent is right for you, they can implant it during your cataract surgery procedure. Once implanted, **iSTENT WILL BEGIN WORKING** to safely and effectively manage your eye pressure. And because of iStent, you may experience a reduction in glaucoma medications; but this will be at the discretion of your prescriber.



Technology has always played an important role in eye care. Today, almost every aspect of vision is connected to a product or procedure that wasn't available even 10 short years ago. The cataract surgery you are scheduled for is a good example of how innovations can make a difference. Every aspect of it uses recently developed technology that will help your doctor improve your vision.

**TODAY, THIS INCLUDES MANAGING YOUR GLAUCOMA.**


## **MAKE TREATING YOUR GLAUCOMA A PART OF TREATING YOUR CATARACT.**

Now, your doctor is able to add another step to your cataract surgery that **ALLOWS YOUR GLAUCOMA TO BE TREATED IN A COMPLETELY NEW WAY.** This is important because once diagnosed with glaucoma, you and most patients like you will spend the rest of your lives taking one, two or even three different medication drops. Unfortunately, you will need to use these drops every day, which will not only be inconvenient, but potentially very expensive. The iStent® Trabecular Micro-Bypass Stent can help with this, and you can have it done at the same time you have cataract surgery. Even so, your eye drop medication use is at the discretion of your prescriber.

## **iSTENT®: THE WORLD'S SMALLEST MEDICAL IMPLANT DELIVERS BIG RESULTS.**

You have mild-to-moderate glaucoma. At this stage of the disease, your vision may be unaffected. But without proper treatment the pressure in your eye could increase and your optic nerve could be damaged. This pressure is caused by the buildup of fluid within your eye. Too much fluid raises pressure, which can cause gradual loss of vision. And while **GLAUCOMA MOVES SLOWLY, ITS DAMAGE IS IRREPARABLE.** Once you start to lose vision, you can never get it back again.

The world's tiniest medical device—the iStent Trabecular Micro-Bypass Stent—is 20,000 times smaller than the intraocular lens (IOL) your doctor will use to replace your cataracts. But the size of iStent is only part of its story. By increasing your eye's ability to drain fluid, this technology is designed to improve the aqueous outflow to safely lower your eye pressure.






IN A US CLINICAL STUDY

# 68%

OF PATIENTS WHO RECEIVED  
iSTENT REMAINED MEDICATION-  
FREE AT 12 MONTHS, WHILE  
SUSTAINING A TARGET IOP OF  $\leq 21$   
MM HG VS. ONLY 50% OF PATIENTS  
WHO UNDERWENT CATARACT  
SURGERY ALONE.<sup>1</sup>



**GLAUKOS**<sup>®</sup>  
*Changing Perspectives*

Glaukos Corporation

26051 Merit Circle • Suite 103 • Laguna Hills • CA 92653 • USA  
tel 949.367.9600 • fax 949.367.9984 • [www.glaukos.com](http://www.glaukos.com)

#### REFERENCE

1. iStent<sup>®</sup> Trabecular Micro-Bypass Stent: Directions for Use, Part # 45-0074. Laguna Hills, Calif: Glaukos Corporation.

#### BRIEF STATEMENT

**INDICATION FOR USE.** The iStent<sup>®</sup> Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication.

**CONTRAINDICATIONS.** The iStent<sup>®</sup> is contraindicated in eyes with primary or secondary angle closure glaucoma, including neovascular glaucoma, as well as in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

**WARNINGS.** Gonioscopy should be performed prior to surgery to exclude PAS, rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. The iStent<sup>®</sup> is MR-Conditional meaning that the device is safe for use in a specified MR environment under specified conditions, please see label for details.

**PRECAUTIONS.** The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the iStent<sup>®</sup> has not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, chronic inflammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after "washout" of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract.

**ADVERSE EVENTS.** The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of  $\geq 1$  line at or after the 3 month visit (7%), posterior capsular opacification (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%), and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information.

**CAUTION:** Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events.

©2012 Glaukos Corporation. iStent and Glaukos are registered trademarks of Glaukos Corporation. 400-0099-2012-US Rev 1